Hepatitis Monthly

Published by: Kowsar

More on Current Evidences on Probiotics as a Novel Treatment for Non-Alcoholic Fatty Liver Disease

Pietro Vajro 1 , * , Claudia Mandato 2 and Roberta D’Aniello 1
Authors Information
1 Department of Medicine and Surgery, University of Salerno, Baronissi-Salerno, Italy
2 AORN Santobono Pediatric Hospital, Naples, Italy
Article information
  • Hepatitis Monthly: August 01, 2013, 13 (8); e13780
  • Published Online: August 27, 2013
  • Article Type: Letter
  • Received: July 24, 2013
  • Revised: July 27, 2013
  • Accepted: August 13, 2013
  • DOI: 10.5812/hepatmon.13780

To Cite: Vajro P, Mandato C, D’Aniello R. More on Current Evidences on Probiotics as a Novel Treatment for Non-Alcoholic Fatty Liver Disease, Hepat Mon. 2013 ; 13(8):e13780. doi: 10.5812/hepatmon.13780.

Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
  • 1. Kelishadi R, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences. Hepat Mon. 2013; 13(4)[DOI][PubMed]
  • 2. Vajro P, Lenta S, Pignata C, Salerno M, D’Aniello R, De Micco I, et al. Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions. Italian J Ped. 2012; 38(1): 55
  • 3. Solga SF, Buckley G, Clark JM, Horska A, Diehl AM. The effect of a probiotic on hepatic steatosis. J Clin Gastroenterol. 2008; 42(10): 1117-9[DOI][PubMed]
  • 4. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012; 57(2): 545-53[DOI][PubMed]
  • 5. Wong VW, Won GL, Chim AM, Chu WC, Yeung DK, Li KC, et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol. 2013; 12(2): 256-62[PubMed]
  • 6. Loguercio C, De Simone T, Federico A, Terracciano F, Tuccillo C, Di Chicco M, et al. Gut-liver axis: a new point of attack to treat chronic liver damage? Am J Gastroenterol. 2002; 97(8): 2144-6[DOI][PubMed]
  • 7. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005; 39(6): 540-3[PubMed]
  • 8. Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011; 52(6): 740-3[DOI][PubMed]
  • 9. Vajro P, Paolella G, Fasano A. Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2013; 56(5): 461-8[DOI][PubMed]
  • 10. Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013; 58(1): 120-7[DOI][PubMed]
  • 11. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013; 57(2): 601-9[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments